CYDY CytoDyn Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1175680 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-171.6%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-351.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets614.7%
Debt / equity—
Current ratio0.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-212.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-08-31 | 2026Q4*2026-05-31 | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $2.06M | $2.28M | $1.65M | $1.80M | $1.71M | $1.85M | $1.52M | $2.30M |
| Operating income | -$6.58M | -$5.64M | -$6.30M | -$21.69M | -$4.95M | -$5.07M | -$4.00M | -$3.71M |
| Pretax income | -$19.94M | -$9.86M | -$4.69M | -$22.61M | -$5.54M | -$5.96M | -$4.76M | -$4.77M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.94M | -$9.86M | -$4.69M | -$22.61M | -$5.54M | -$5.96M | -$4.76M | -$4.77M |
| EBITDA | -$6.56M | -$5.63M | -$6.30M | -$21.68M | -$4.94M | -$5.06M | -$4.00M | -$3.70M |
| EPS (basic) | -0.01 | — | 0.00 | -0.02 | 0.00 | — | 0.00 | 0.00 |
| EPS (diluted) | -0.01 | — | 0.00 | -0.02 | 0.00 | — | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 1.38B | — | 1.28B | 1.26B | 1.25B | — | 1.23B | 1.22B |
| Balance sheet | ||||||||
| Cash & equivalents | $16.36M | $11.85M | $15.65M | $4.98M | $9.33M | $11.90M | $16.40M | $21.34M |
| Current assets | $18.98M | $13.88M | $18.44M | $8.84M | $13.35M | $17.88M | $20.98M | $24.63M |
| Total assets | $19.05M | $13.97M | $18.50M | $8.94M | $13.48M | $18.05M | $21.19M | $24.88M |
| Current liabilities | $49.70M | $53.73M | $50.43M | $85.11M | $69.42M | $70.52M | $70.56M | $70.63M |
| Long-term debt | $35.81M | $38.34M | $40.53M | $42.17M | $43.78M | $45.35M | $45.84M | $46.08M |
| Total debt | $35.81M | $38.34M | $40.53M | $42.17M | $43.78M | $45.35M | $45.84M | $46.08M |
| Total liabilities | $117.13M | $123.69M | $122.78M | $128.68M | $112.99M | $114.09M | $114.17M | $114.27M |
| Shareholders' equity | -$98.07M | -$109.72M | -$104.29M | -$119.75M | -$99.50M | -$96.04M | -$92.98M | -$89.39M |
| Net debt | $19.45M | $26.49M | $24.88M | $37.19M | $34.45M | $33.45M | $29.44M | $24.75M |
| Shares outstanding | 1.45B | 1.37B | 1.36B | 1.27B | 1.26B | 1.25B | 1.23B | 1.22B |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.73M | -$4.93M | -$5.52M | -$4.35M | -$2.45M | -$5.66M | -$4.96M | -$3.59M |
| Investing cash flow | $0 | — | — | — | $0 | — | — | — |
| Financing cash flow | $12.23M | $1.13M | $16.19M | $0 | -$121,000 | $1.17M | $21,000 | $0 |
| Depreciation & amortization | $19,000 | $4,000 | $4,000 | $5,000 | $4,000 | $4,000 | $5,000 | $4,000 |
| Stock-based compensation | $524,000 | $823,000 | $445,000 | $183,000 | $179,000 | $599,000 | $340,000 | $537,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.